СОВРЕМЕННЫЕ МЕТОДЫ ЛЕЧЕНИЯ МИГРЕНИ ОСНОВАННЫЙ НА ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЕ
Ключевые слова:
мигрень, головная боль, лечение, острый, профилактический, поведенческая терапияАннотация
В статье рассматриваются современные принципы лечения мигрени в период обострения приступов, а также методы профилактического лечения основанные на принципах доказательной медицины. Обсуждаются основные показания, методы фармакологического и нефармакологического лечения мигрени, показавших наиболее высокую эффективность в превентивной терапии заболевания. Подробно рассмотрены методы поведенческой и физикальной терапии, использование лечебной фитотерапии, минералов и витаминов в профилактике мигренозных пароксизмов.
Библиографические ссылки
Артеменко А.Р., Куренков А.Л., Беломестова К.В. Классификация, диагностика и лечение хронической мигрени: обзор новых данных. Журнал неврологии и психиатрии им. С.С. Корсакова 2013;113(11):91–6.
Артеменко А.Р., Куренков А.Л. Хроническая мигрень. Москва: ABV-press; 2012.
Головачева В.А., Парфенов В.А. Когнитивно-поведенческая терапия в лечении пациентов с мигренью. Неврологический журнал.vol-20. No.3, 2015; pp.37-43.
Данилов А.Б., Данилов Ал.Б. Управление болью. Биопсихосоциальный подход. М.: АММ ПРЕСС; 2012.
Данилов А.Б., Подымова И.Г., Филатова Е.Г., Екушева Е.В., Табеева Г.Р., Осипова В.В., Азимова Ю.Э., Амелин А.В., Корешкина М.И., Рачин А.П. Лечение мигренозного приступа: эффективность и безопасность. Медицинский консилиум. 2013;15(2):19-22.
Марчук М.С. Мигрень: рекомендации по лечению и профилактике 2019 года. Украинский медицинский журнал. 2019-01-21.
Табаева Г.Р. Принципы лечения мигрени. Русский медицинский журнал. 2007; 10: 802–5.
Табеева Г.Р. Профилактика мигрени. Руководство. М.: Пульс, 2008. 100 с.
Филатова Е.Г. Терапия приступов мигрени. Русский медицинский журнал. 2013;21(16):862-865.
Аmerican Headache Society (2019) The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache, 59(1): 1–18.
Aurora S.K., Winner P., Freeman M.C. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358–73.
Bendtsen L. Drug and nondrug treatment in tension-type headache. Ther Adv Neurol Disord 2009; 2(3): 155–161.
Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tensiontype headache – Report of an EFNS task force. Eur J Neurol. 2010 Nov;17(11):1318–25.
Biondi D. Physical treatments for headache: A structured review. Headache. 2005 Jun;45(6):738–46.
Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297(13):1443–1454.
Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34:853-869. https://doi.org/10.1177/0333102414527648
Campbell JK, Penzien DB, Wall EM. Evidence-based guidelines for migraine headache: Behavioral and physical treatments. US Headache Consortium 2000.
Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369–1373.
Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336(7657):1359–1361.
Detsky ME, McDonald DR, Baerlocher MO, Tomlinson GA, McCrory DC, Booth CM. Does this patient with headache have a migraine or need neuroimaging? JAMA. 2006;296:1274-1283. doi:10.1001/jama.296.10.1274.
Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG; Bi-Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology. 2002;58(11):1660–1665.
Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006;46:182-191.
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS, European Federation of Neurological Societies EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981.
Gaul C, EIsmann R, Schmidt T, et al. Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia. 2009 Oct;29(10):1069–78. doi: 10.1111/j.1468-2982.2009.01841.x. Epub 2009 Apr 2.
Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan [published correction appears in Cephalalgia. 2008;28(6):679]. Cephalalgia. 2008;28(4):383–391.
Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS ONE. 2019;14(3):e0212785.
Halker R.B., Hastriter E.V., Dodick D.W. Chronic daily headache: an evidence-based and s ystematic approach to a challenging problem. Neurology. 2011; 76: 37–43.
Hamelsky S.W., Kolodner K.B., Steiner T.J., Stewart W.F. Migraine, quality of life, and depression: a population–based case–control study // Neurology. 2000 Sep 12. Vol. 55 (5). Р. 629–635.
Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–1353.
Holroyd KA, Drew JB. Behavioral approaches to the treatment of migraine. Semin Neurol. 2006 Apr;26(2):199–207.
Lemstra M, Stewart B, Olszynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache 2002; 42(9): 845–854.
Lipton R.B., Dodick D., Kolodner K., Hettiarachchi J. Evaluation of quality of life and disability in patients with migraine and nonmigraine headaches in primary care // Relpax Worldwide Country Advisory Board. Poster presentation.2005 May 22-24, Berlin, Germany.
MacGregor E.A., Steiner T.J., Davies P.T.G. Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache. 3rd ed. 2010.
Marmura M.J., Silberstein S.D., Schwedt T.J. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies // Headache. 2015. V. 55. P. 3–20.
Matchar DB, Young WB, Rosenberg JH, et al.; U.S. Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Accessed December 16, 2010.
Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49(7):971–982.
Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41(2):119–128.
Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21(3):173–175.
Milton J. Psychoanalysis and cognitive behavior therapy – rival paradigms or common ground? Int J Psychoanal. 2001 Jun;82 (Pt 3):431–47.
Morey SS. Guidelines on migraine: part 2. General principles of drug therapy. Am Fam Physician. 2000;62(8):1915–1917.
Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: а systematic review. Cephalalgia. 2010;30:599-609.
Ozcan C, Vayisoglu Y, Doğu O, Görür K. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryngol. 2006;27(5):314-318.
Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003;7:51–4. .
Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–715.
Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3–S9.
Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46:642–648.
Silberstein SD. A new frontier for headache. Frontiers in Neurology. 2010;1:135.
Silberstein S.D., Blumenfeld A.M., Cady R.K. et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013;331(1–2): 48–56.
Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002;22(7):491–512.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–1345.
Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice. 2nd ed. Chapter 16. London: Informa Healthcare; 2002. p. 92.
Silberstein, S.D. Multispecialty consensus on di- agnosis and treatment of headache / S.D.Silberstein, J.Rosenberg // Neurology. – 2000. – Vol.54. – P.1553.
Silberstein S.D. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standarts Subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754–62.
Singh A, Alter HJ, Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature [published correction appears in Acad Emerg Med. 2009;16(5):435]. Acad Emerg Med. 2008;15(12):1223–1233.
Steiner T.J., Paemeleire K., Jensen R. et al. European principles of management of common headache disorders in primary care // J Headache Pain. 2007 Oct. Vol. 8. Suppl 1. Р. 3–47.2. 3.
Sun-Edelstein C, Mauskop A. Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache. 2011 Mar;51(3):469–83.
Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007;41(11):1782–1791
Tepper SJ, Bigal M, Rapoport A, Sheftell F. Alternative therapies: evidence-based evaluation in migraine. Headache Care. 2006;3(2–3):57–64.
Tfelt-Hansen, P; Tfelt-Hansen, J (2009). "Verapamil for cluster headache. Clinical pharmacology and possible mode of action". Headache. Review. 49 (1): 117–25.
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–69.
Wallasch TM, Kropp P. Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. J Headache Pain. 2012 Oct;13(7):521–9.
Wang SJ. Epidemiology of migraine and other types of headache in Asia. Curr Neurol Neurosci Rep 2003;3:104–8.
